nafazatrom has been researched along with Coronary Disease in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Coker, SJ; Parratt, JR | 2 |
| Abrams, GD; Jolly, SR; Lucchesi, BR; Murtagh, JJ; Pitt, B; Shea, MJ | 1 |
| Driscoll, EM; Lucchesi, BR; Pitt, B; Romson, JL; Shea, MJ | 1 |
| Bednar, M; Mullane, KM; Pinto, A; Smith, B | 1 |
| Bolli, R; Charlat, ML; Hartley, CJ; Kim, HS; Michael, LH; O'Neill, PG; Pocius, J; Roberts, R; Zhu, WX | 1 |
| Mehta, J; Mehta, P; Roy, L | 1 |
1 trial(s) available for nafazatrom and Coronary Disease
| Article | Year |
|---|---|
Lack of efficacy of nafazatrom, a novel anti-thrombotic compound, in patients with coronary artery disease.
Topics: 6-Ketoprostaglandin F1 alpha; beta-Thromboglobulin; Blood Pressure; Coronary Disease; Exercise Test; Female; Fibrinolytic Agents; Heart Rate; Humans; Male; Middle Aged; Platelet Count; Platelet Factor 4; Pyrazoles; Pyrazolones; Thromboxane B2 | 1985 |
6 other study(ies) available for nafazatrom and Coronary Disease
| Article | Year |
|---|---|
The effects of nafazatrom on arrhythmias and prostanoid release during coronary artery occlusion and reperfusion in anaesthetized greyhounds.
Topics: 6-Ketoprostaglandin F1 alpha; Anesthesia; Animals; Arrhythmias, Cardiac; Coronary Disease; Dogs; Epoprostenol; Female; Fibrinolytic Agents; Male; Perfusion; Prostaglandins; Pyrazoles; Pyrazolones; Thromboxane B2 | 1984 |
Beneficial effects of nafazatrom on ischemic reperfused myocardium.
Topics: Animals; Blood Pressure; Coronary Circulation; Coronary Disease; Dogs; Electrocardiography; Fibrinolytic Agents; Male; Myocardial Infarction; Pyrazoles; Pyrazolones; Time Factors | 1984 |
The beneficial effects of nafazatrom (BAYg6575) on experimental coronary thrombosis.
Topics: Adenosine Diphosphate; Animals; Blood Pressure; Collagen; Coronary Circulation; Coronary Disease; Dogs; Electrocardiography; Fibrinolytic Agents; Male; Platelet Aggregation; Pyrazoles; Pyrazolones | 1984 |
Arachidonic acid cascade and the generation of ischemia- and reperfusion-induced ventricular arrhythmias.
Topics: Animals; Arachidonic Acid; Arachidonic Acids; Arrhythmias, Cardiac; Coronary Disease; Dogs; Epoprostenol; Iloprost; Norepinephrine; Perfusion; Pyrazoles; Pyrazolones; Receptors, Prostaglandin; Receptors, Thromboxane; Thromboxanes | 1985 |
Nafazatrom-induced salvage of ischemic myocardium in anesthetized dogs is mediated through inhibition of neutrophil function.
Topics: 4,5-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amine; Animals; Anti-Inflammatory Agents; Arachidonic Acid; Arachidonic Acids; Cell Aggregation; Coronary Disease; Dogs; Fibrinolytic Agents; Glucuronidase; Male; Myocardial Infarction; Myocardium; Neutrophils; Platelet Aggregation; Pyrazoles; Pyrazolones; Superoxides | 1985 |
Lipoxygenase inhibitor nafazatrom fails to attenuate postischaemic ventricular dysfunction.
Topics: Animals; Coronary Disease; Dogs; Heart; Hemodynamics; Leukocyte Count; Lipoxygenase; Lipoxygenase Inhibitors; Myocardium; Neutrophils; Pyrazoles; Pyrazolones | 1987 |